About IVDiagnostics


“What If Cancer Could Be Dedected Without Taking Blood?”

Cancer cells spread through the circulatory system as “circulating tumor cells” (CTCs) and represent unique diagnostic targets. CTCs are released from primary tumors into blood circulation and then lodge at distant organs to initiate new cancer growth. Thus circulating tumor cells constitute the major cause for mortality among cancer patients. Recent advancements in detection and characterization of CTCs can have a significant impact on early cancer detection. For instance, the quantization of CTCs can be used for prognosis of the outcomes of metastatic diseases. In another example, identification of cancer stem cells, a subpopulation of CTCs believed to be tumorigenic, can be used for identifying metastasis and recurrence of disease.


Our mission is to provide oncologists and pathologists with better diagnostics tools for measuring and monitoring circulating tumor cells. By doing so, physicians will be able to determine effectiveness of therapy and thus save lives.


IVDiagnostics was formed to develop, test and market more effective diagnostic tools for addressing rare circulating tumor cells and blood borne diseases. By collaborating with several academic and commercial partners, the company has accelerated its research and development.

Within a short period of time, IVDiagnostics has assembled a team of researchers, scientists, medical advisors, scientific advisors and clinicians — all passionate about moving toward personalized medicine and focused on assisting physicians with the knowledge of ”what’s inside” the body, and providing the ability to monitor the patient’s circulatory system with minimally invasive techniques.

Our Strengths

Innovative Ideas


Advanced Technology


Clear Communication


Management  Advisory Team

Kevin Vanderground

General Counsel, Partner at CCHA Law

Joerg Schreiber

Vice President of Product Management and Quality Assurance

Harry Horn

Director of Regulatory Affairs

Medical Advisory Board

The Medical Advisory Board consists of physicians with specific expertise in clinical applications in the fields on Oncology, Hematology, and Surgical Oncology.

Dieter Enzmann, M.D.

Leo G. Rigler Chair and Professor of Radiological Sciences, David Geffen School of Medicine at UCLA

Joseph N. Espat, M.D., MS, FACS

Chairman of the Department of Surgery, Chief of Surgical Oncology, and Director of the Cancer Center at Roger Williams Medical Center

Tom Galouzis, M.D.

Oncology Surgeon, Sisters of St Francis Healthcare Services, Franciscan St. Anthony’s Health, Adjunct Professor, Purdue North Central

Noah Hahn, M.D.

Assistant Professor of Medicine, Division of Hematology/Oncology, IU Simon Cancer Center

Scientific Advisory Board

Mary J. Hendrix, Ph.D.

Newly anounced President of Shepard’s University; past President and Scientific Director of Stanley Manne Institute at Lurie’s Children Hospital

Roman Dziarski, Ph.D.

Professor of Microbiology and Immunology at IU School of Medicine

Dipika Gupta, Ph.D.

Associate Professor of Biochemistry and Molecular Biology at IU School of Medicine

Philip S. Low, Ph.D.

Distinguished Professor of Chemistry at Purdue University

Waclaw Szybalski, D. Sci.

Professor Emeritus of Oncology, University of Wisconsin and Founder of Gene Journal